#United States #Burlington #Clinical Trials #Labcorp #MLM Medical Labs

Labcorp's Strategic Expansion in Clinical Trials

Labcorp, recognized as a leader in laboratory services globally, has announced a significant strategic acquisition of MLM Medical Labs (MLM), a prominent provider of central and specialty laboratory services with a robust operational presence in the United States, Germany, and South Africa. This acquisition positions Labcorp uniquely within the laboratory services industry, making it the only provider with a fully owned laboratory network spanning four continents, including North America, Europe, Asia, and Africa.

Enhancing Global Capabilities

The acquisition is set to considerably bolster Labcorp's capacity as an independent central lab service provider, enhancing key areas of clinical research. By integrating MLM's established laboratory framework and specialized service model, Labcorp is poised to amplify its biomarker and specialty testing capabilities. This strategic move meets the growing demand from clinical trial sponsors for a comprehensive and scientifically backed laboratory network that can support the increasingly complex landscape of drug development.

Brian Caveney, M.D., Labcorp’s EVP and president of biopharma laboratory services, emphasized the need for scientific prowess and global operational flexibility among clinical trial sponsors today. He stated, "MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies. Together, we are well positioned to provide the capabilities, regional expertise, and high-touch support sponsors need to advance innovative therapies worldwide."

With this acquisition, Labcorp aims to provide seamless oversight and support for complex multinational trials. It ensures consistent scientific, operational, and regulatory guidance from a single trusted partner throughout the clinical development process. This is particularly crucial in critical research markets, with Africa benefiting from the acquisition as MLM operates the continent’s first fully CAP-accredited central laboratory, thereby extending Labcorp's footprint in key clinical research regions.

A Commitment to Innovation and Quality

The acquisition is a testament to Labcorp's ongoing strategy to invest in central laboratory services that cater to the evolving needs of clinical trial sponsors globally. By consolidating their resources, Labcorp and MLM are set to enhance not only their scientific and regulatory capabilities but also expand access to biomarker and specialty testing that supports the modernization of clinical development programs. This effort reflects a deep commitment to advancing medical science and improving health outcomes.

Evercore has acted as the exclusive financial advisor to Labcorp for this transaction, while Pierson Ferdinand and Hogan Lovells have provided legal counsel, indicating the significant nature and anticipated impact of this acquisition.

Conclusion

Labcorp’s acquisition of MLM Medical Labs marks a decisive step forward in its mission to provide innovative and comprehensive laboratory services. As Labcorp continues to forge its path as a leader in clinical trials and laboratory services, this acquisition underscores the company's dedication to enhancing the capabilities and support it provides to sponsors navigating the complexities of clinical research. With nearly 71,000 employees serving clients in approximately 100 countries, Labcorp is well-equipped to maintain its pioneering status in the healthcare sector by delivering superior insights and advancing science that improve lives globally.

For more information about Labcorp's extensive capabilities and services, visit Labcorp's website.